176 related articles for article (PubMed ID: 28652015)
1. Landscape of Innovation for Cardiovascular Pharmaceuticals: From Basic Science to New Molecular Entities.
Beierlein JM; McNamee LM; Walsh MJ; Kaitin KI; DiMasi JA; Ledley FD
Clin Ther; 2017 Jul; 39(7):1409-1425.e20. PubMed ID: 28652015
[TBL] [Abstract][Full Text] [Related]
2. Timelines of translational science: From technology initiation to FDA approval.
McNamee LM; Walsh MJ; Ledley FD
PLoS One; 2017; 12(5):e0177371. PubMed ID: 28481922
[TBL] [Abstract][Full Text] [Related]
3. Patterns of Innovation in Alzheimer's Disease Drug Development: A Strategic Assessment Based on Technological Maturity.
Beierlein JM; McNamee LM; Walsh MJ; Ledley FD
Clin Ther; 2015 Aug; 37(8):1643-51.e3. PubMed ID: 26243074
[TBL] [Abstract][Full Text] [Related]
4. Modeling timelines for translational science in cancer; the impact of technological maturation.
McNamee LM; Ledley FD
PLoS One; 2017; 12(3):e0174538. PubMed ID: 28346525
[TBL] [Abstract][Full Text] [Related]
5. The FDA and the new biology.
Simari RD; Chen H; Burnett JC
J Cardiovasc Transl Res; 2008 Dec; 1(4):246-7. PubMed ID: 20559929
[TBL] [Abstract][Full Text] [Related]
6. Contribution of NIH funding to new drug approvals 2010-2016.
Galkina Cleary E; Beierlein JM; Khanuja NS; McNamee LM; Ledley FD
Proc Natl Acad Sci U S A; 2018 Mar; 115(10):2329-2334. PubMed ID: 29440428
[TBL] [Abstract][Full Text] [Related]
7. An analysis of original research contributions toward FDA-approved drugs.
Patridge EV; Gareiss PC; Kinch MS; Hoyer DW
Drug Discov Today; 2015 Oct; 20(10):1182-7. PubMed ID: 26113307
[TBL] [Abstract][Full Text] [Related]
8. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
Kwok M; Foster T; Steinberg M
Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
[TBL] [Abstract][Full Text] [Related]
9. The impact of external innovation on new drug approvals: A retrospective analysis.
Liu X; Thomas CE; Felder CC
Int J Pharm; 2019 May; 563():273-281. PubMed ID: 30664998
[TBL] [Abstract][Full Text] [Related]
10. An overview of FDA-approved new molecular entities: 1827-2013.
Kinch MS; Haynesworth A; Kinch SL; Hoyer D
Drug Discov Today; 2014 Aug; 19(8):1033-9. PubMed ID: 24680947
[TBL] [Abstract][Full Text] [Related]
11. Availability of comparative efficacy data at the time of drug approval in the United States.
Goldberg NH; Schneeweiss S; Kowal MK; Gagne JJ
JAMA; 2011 May; 305(17):1786-9. PubMed ID: 21540422
[TBL] [Abstract][Full Text] [Related]
12. 2017 in review: FDA approvals of new molecular entities.
Kinch MS; Griesenauer RH
Drug Discov Today; 2018 Aug; 23(8):1469-1473. PubMed ID: 29751111
[TBL] [Abstract][Full Text] [Related]
13. How drugs are developed and approved by the FDA: current process and future directions.
Ciociola AA; Cohen LB; Kulkarni P;
Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
[TBL] [Abstract][Full Text] [Related]
14. Translatability score revisited: differentiation for distinct disease areas.
Wendler A; Wehling M
J Transl Med; 2017 Nov; 15(1):226. PubMed ID: 29100553
[TBL] [Abstract][Full Text] [Related]
15. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
Harapanhalli RS
Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
[TBL] [Abstract][Full Text] [Related]
16. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
17. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
Moore TJ; Furberg CD
JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
[TBL] [Abstract][Full Text] [Related]
18. 2014 in review: FDA approval of new drugs.
Kinch MS
Drug Discov Today; 2017 Apr; 22(4):620-624. PubMed ID: 26100738
[TBL] [Abstract][Full Text] [Related]
19. New therapeutic agents marketed in 1995.
Hussar DA
Pa Med; 1996 Apr; 99(4):43-6. PubMed ID: 8935886
[TBL] [Abstract][Full Text] [Related]
20. Building a drug development database: challenges in reliable data availability.
Audibert C; Romine M; Caze A; Daniel G; Leff J; McClellan M
Drug Dev Ind Pharm; 2017 Jan; 43(1):74-78. PubMed ID: 27494335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
